Dalton Grows Sterile Manufacturing Capacity
cGMP line will fill vials, syringes, and cartridges, while supporting small-scale commercial production.
Dalton Pharma Services, a current good manufacturing practice (cGMP) pharmaceutical organization and member of the Seikagaku Group, is expanding its pharmaceutical manufacturing capacity. The addition features a new fully automated cGMP sterile filling line, intended to fill vials, syringes, and cartridges under isolator technology.
Combined with a new lyophilizer, the new line reportedly is able to support small-scale commercial manufacturing and offers complete sterile finished dosage form manufacturing capabilities. The expansion also includes additional cGMP non-sterile powder filling capacity, effectiveness in multi-kilogram active pharmaceutical ingredient (API) manufacturing, and organic solvent handling and storage infrastructure.
"This major investment in the expansion of our sterile manufacturing capabilities enables us to meet the needs of our customers as their critical products advance to commercialization," notes Peter Pekos, CEO of Dalton Pharma Services.
